tetano
Editor, Senior Moderator
Nat Commun. 2018 Aug 22;9(1):3361. doi: 10.1038/s41467-018-05482-0.
[h=1]Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies.[/h] Pardi N[SUP]1[/SUP], Parkhouse K[SUP]2[/SUP], Kirkpatrick E[SUP]3,[/SUP][SUP]4[/SUP], McMahon M[SUP]3[/SUP], Zost SJ[SUP]2[/SUP], Mui BL[SUP]5[/SUP], Tam YK[SUP]5[/SUP], Karik? K[SUP]6[/SUP], Barbosa CJ[SUP]5[/SUP], Madden TD[SUP]5[/SUP], Hope MJ[SUP]5[/SUP], Krammer F[SUP]3[/SUP], Hensley SE[SUP]7[/SUP], Weissman D[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Currently available influenza virus vaccines have inadequate effectiveness and are reformulated annually due to viral antigenic drift. Thus, development of a vaccine that confers long-term protective immunity against antigenically distant influenza virus strains is urgently needed. The highly conserved influenza virus hemagglutinin (HA) stalk represents one of the potential targets of broadly protective/universal influenza virus vaccines. Here, we evaluate a potent broadly protective influenza virus vaccine candidate that uses nucleoside-modified and purified mRNA encoding full-length influenza virus HA formulated in lipid nanoparticles (LNPs). We demonstrate that immunization with HA mRNA-LNPs induces antibody responses against the HA stalk domain of influenza virus in mice, rabbits, and ferrets. The HA stalk-specific antibody response is associated with protection from homologous, heterologous, and heterosubtypic influenza virus infection in mice.
PMID: 30135514 DOI: 10.1038/s41467-018-05482-0
[h=1]Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies.[/h] Pardi N[SUP]1[/SUP], Parkhouse K[SUP]2[/SUP], Kirkpatrick E[SUP]3,[/SUP][SUP]4[/SUP], McMahon M[SUP]3[/SUP], Zost SJ[SUP]2[/SUP], Mui BL[SUP]5[/SUP], Tam YK[SUP]5[/SUP], Karik? K[SUP]6[/SUP], Barbosa CJ[SUP]5[/SUP], Madden TD[SUP]5[/SUP], Hope MJ[SUP]5[/SUP], Krammer F[SUP]3[/SUP], Hensley SE[SUP]7[/SUP], Weissman D[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Currently available influenza virus vaccines have inadequate effectiveness and are reformulated annually due to viral antigenic drift. Thus, development of a vaccine that confers long-term protective immunity against antigenically distant influenza virus strains is urgently needed. The highly conserved influenza virus hemagglutinin (HA) stalk represents one of the potential targets of broadly protective/universal influenza virus vaccines. Here, we evaluate a potent broadly protective influenza virus vaccine candidate that uses nucleoside-modified and purified mRNA encoding full-length influenza virus HA formulated in lipid nanoparticles (LNPs). We demonstrate that immunization with HA mRNA-LNPs induces antibody responses against the HA stalk domain of influenza virus in mice, rabbits, and ferrets. The HA stalk-specific antibody response is associated with protection from homologous, heterologous, and heterosubtypic influenza virus infection in mice.
PMID: 30135514 DOI: 10.1038/s41467-018-05482-0